{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:13Z","timestamp":1793228113057,"version":"4.5.0"},"reference-count":20,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,10,3]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1136\/ejhpharm-2023-003928","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:20:11Z","timestamp":1698254411000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["In-use stability of ready-to-administer daratumumab subcutaneous injection solution in plastic syringes"],"prefix":"10.1136","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5717-4560","authenticated-orcid":false,"given":"Laura","family":"Knoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Thiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M H","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Tuerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2025032704500679000_32.2.154.1","unstructured":"European Medicines Agency . Assessment report darzalex. 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/darzalex-h-c-4077-ii-0044-epar-assessment-report-variation_en.pdf [Accessed 23 Feb 2023]."},{"key":"2025032704500679000_32.2.154.2","unstructured":"European Medicines Agency . Summary of product characteristics darzalex 1800 mg injection solution. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf [Accessed 23 Feb 2023]."},{"key":"2025032704500679000_32.2.154.3","unstructured":"European Medicines Agency . Assessment report darzalex. 2020. Available: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/darzalex-h-c-4077-x-0032-epar-assessment-report-extension_en.pdf [Accessed 15 Jun 2023]."},{"key":"2025032704500679000_32.2.154.4","doi-asserted-by":"crossref","unstructured":"Mangoni G , Selmin F , Camuffo L , et al . 3PC-015\u2005short term stability of diluted solutions of the monoclonal antibody daratumumab. 25th EAHP Congress, 25th\u201327th March 2020, Gothenburg, Sweden; March 2020 doi:10.1136\/ejhpharm-2020-eahpconf.62","DOI":"10.1136\/ejhpharm-2020-eahpconf.62"},{"key":"2025032704500679000_32.2.154.5","unstructured":"International Conference on Harmonization . Harmonized tripartite guidelines for validation of analytical procedures: text and methodology Q2 (R1). 1995. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf [Accessed 6 Mar 2023]."},{"key":"2025032704500679000_32.2.154.6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: a practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"MAbs"},{"key":"2025032704500679000_32.2.154.7","unstructured":"NHS Pharmaceutical Quality Assurance Committee . A standard protocol for deriving and assessment of stability, part 2 aseptic preparations (Biopharmaceuticals). 2021. Available: https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2017\/03\/Stability-Part-2-Biopharmaceuticals-v5.pdf [Accessed 16 Jun 2023]."},{"key":"2025032704500679000_32.2.154.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"2025032704500679000_32.2.154.9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.xphs.2019.09.018","article-title":"An industry perspective on forced degradation studies of biopharmaceuticals: survey outcome and recommendations","volume":"109","author":"Halley","year":"2020","journal-title":"J Pharm Sci"},{"key":"2025032704500679000_32.2.154.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchromb.2017.05.010","article-title":"Protocols for the analytical characterization of therapeutic monoclonal antibodies. I \u2013 non-denaturing chromatographic techniques","volume":"1058","author":"Goyon","year":"2017","journal-title":"Journal of Chromatography B"},{"key":"2025032704500679000_32.2.154.11","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1007\/s00216-018-1561-1","article-title":"A generic workflow for the characterization of therapeutic monoclonal antibodies-application to daratumumab","volume":"411","author":"Duivelshof","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"2025032704500679000_32.2.154.12","first-page":"246","article-title":"Prolonged in-use stability of diluted atezolizumab in commercial Intravenouse bags","volume":"25","author":"Hui","year":"2021","journal-title":"Int J Pharm Compd"},{"key":"2025032704500679000_32.2.154.13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2016.01.008","article-title":"Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues","volume":"58","author":"Bardo-Brouard","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025032704500679000_32.2.154.14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pharma.2017.06.003","article-title":"Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags","volume":"75","author":"Vieillard","year":"2017","journal-title":"Ann Pharm Fr"},{"key":"2025032704500679000_32.2.154.15","first-page":"261","article-title":"Physico-chemical stability of mabthera drug-product solution for subcutaneous injection under in-use conditions with different administration materials","volume":"19","author":"Mueller","year":"2015","journal-title":"Int J Pharm Compd"},{"key":"2025032704500679000_32.2.154.16","unstructured":"Nalenz H , Sch\u00f6nhammer K , Dietel E , et al . Compatibility of herceptin SC with SC administration materials. ESCP Symposium Abstract book; 2014"},{"key":"2025032704500679000_32.2.154.17","doi-asserted-by":"crossref","unstructured":"Almasi J , Thiesen J , Kr\u00e4mer I . Physicochemical stability of durvalumab (Imfinzi\u00ae) concentrate for solution in original vials after first opening. Pharm Technol Hosp Pharm 2023;8. doi:10.1515\/pthp-2023-0008","DOI":"10.1515\/pthp-2023-0008"},{"key":"2025032704500679000_32.2.154.18","unstructured":"Usage information: HYLASE\u00ae Dessau 1500 I.U, powder for solution for injection. 2012. Available: https:\/\/www.medikamente-per-klick.de\/images\/ecommerce\/06\/78\/06785611_2012-06_de_o.pdf [Accessed 30 Jun 2023]."},{"key":"2025032704500679000_32.2.154.19","first-page":"10781552231179185","article-title":"Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy","volume":"10781552231179185","author":"Almasi","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025032704500679000_32.2.154.20","doi-asserted-by":"crossref","unstructured":"Crauste-Manciet S , Kr\u00e4mer I , Lagarce F , et al . GERPAC consensus conference \u2013 guidance on the assignment of microbiological shelf-life for hospital pharmacy aseptic preparations. Pharmaceutical Technology in Hospital Pharmacy 2020;5. doi:10.1515\/pthp-2020-0001","DOI":"10.1515\/pthp-2020-0001"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2023-003928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:00:07Z","timestamp":1743076807000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2023-003928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,21]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/ejhpharm-2023-003928"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2023-003928","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}